Recent developments highlight positive clinical trial results for Anixa’s breast cancer vaccine and continued buy recommendations from analysts. News coverage also discusses the company’s stock performance relative to medical peers and momentum interest.

• D. Boral Capital maintained a buy recommendation on Anixa Biosciences in December 2025 [N1].
• The Phase 1 clinical trial of Anixa’s breast cancer vaccine showed safety and was well tolerated, with immune responses observed in 74% of participants [N2].
• Analyses in late 2025 noted Anixa’s stock outperformance relative to medical peers and highlighted the company as a momentum pick [N3][N4][N5].
• Anixa received notice of allowance for its breast cancer vaccine technology patent in China in August 2025, supporting its intellectual property position [N1].

Anixa has demonstrated clinical progress with its CAR-T therapy and breast cancer vaccine, including positive safety and immune response data from Phase 1 trials. Its strategic collaborations with leading cancer research centers and licensing agreements with respected institutions provide a strong scientific foundation. The company’s focus on difficult-to-treat cancers such as ovarian cancer and triple-negative breast cancer addresses significant unmet needs. Its strong liquidity position as of April 2026 supports ongoing development activities. Continued clinical milestones and successful partnerships could enhance the company’s prospects.

Anixa remains an early-stage biotechnology company with no current revenue from its therapeutics or vaccine programs and a history of net losses. The company depends on strategic partnerships for commercialization, lacking internal manufacturing and marketing capabilities. Clinical development carries inherent risks including patient enrollment challenges, regulatory approval uncertainties, and potential failure to demonstrate efficacy. Competition from larger firms with greater resources is significant. The company’s ability to raise additional capital on acceptable terms is uncertain, and dilution risk exists. Operational and financial challenges typical of early-stage biotech companies may adversely affect progress.

Anixa’s competitive advantages include proprietary licensed technologies for CAR-T therapy and cancer vaccines targeting specific proteins associated with ovarian and breast cancers. Collaborations with reputable research institutions such as The Wistar Institute, Cleveland Clinic, and Moffitt Cancer Center provide scientific expertise and clinical trial capabilities. The company’s focus on novel immunotherapies for solid tumors, an area with significant unmet medical need, and its early clinical progress contribute to its differentiation. However, the company faces competition from larger, better-funded pharmaceutical and biotechnology firms with more extensive development and commercialization experience.

• Clinical Development Risks: Enrollment, trial execution, and achieving primary endpoints in clinical trials for CAR-T therapy and vaccines are uncertain and may delay or prevent regulatory approval.
• Regulatory Approval Risks: The company has not previously submitted a Biologics License Application or New Drug Application; regulatory processes are lengthy and complex.
• Financial Risks: Anixa has a history of losses and may require additional funding, which may not be available on acceptable terms, potentially causing dilution or operational constraints.
• Competitive Risks: The company faces competition from larger, better-funded pharmaceutical and biotechnology companies that may develop more effective or safer therapies.
• Supply Chain Risks: Dependence on specialty raw materials from limited suppliers may cause delays or increased costs in manufacturing clinical or commercial products.
• Partnership Risks: The company relies on strategic collaborations for commercialization; failure to establish or maintain these partnerships could adversely affect business prospects.

• Anixa Biosciences Inc is a biotechnology company focused on developing therapies and vaccines addressing critical unmet needs in oncology [S1].
• The company’s therapeutics program includes liraltagene autoleucel (lira-cel), a novel CAR-T cell therapy initially targeting ovarian cancer, developed by its subsidiary Certainty Therapeutics [S1].
• Certainty holds an exclusive worldwide royalty-bearing license from The Wistar Institute for chimeric endocrine receptor targeted therapy technology [S1].
• Certainty’s equity stake held by Wistar was 4.1% as of October 31, 2025, after dilution from company funding [S1].
• Lira-cel is in a Phase 1 dose-escalation clinical trial for recurrent epithelial ovarian cancer, conducted at the H. Lee Moffitt Cancer Center, with up to 24 to 48 patients planned [S1].
• The Phase 1 trial has treated multiple dose cohorts with increasing doses, and treatments have been well-tolerated with anecdotal signs of efficacy including extended patient survival [S1].
• The company holds exclusive worldwide royalty-bearing licenses from Cleveland Clinic for breast cancer vaccine technology targeting alpha-lactalbumin protein and ovarian cancer vaccine technology targeting AMHR2-ED protein [S1].
• The breast cancer vaccine is focused on triple-negative breast cancer (TNBC), the most lethal form, and has completed a Phase 1 multiple-ascending dose trial with 35 participants across three cohorts [S1].
• The Phase 1 breast cancer vaccine trial met all primary endpoints, showed immune responses in 74% of subjects, and was safe and well-tolerated with mainly injection-site irritation as adverse events [S1].
• Combination of the breast cancer vaccine with pembrolizumab (Keytruda) generated antigen-specific T cell responses without major additional side effects [S1].
• The ovarian cancer vaccine technology is part of the NCI’s PREVENT program, which supports pre-clinical development and IND enabling studies, performed at NCI facilities with no material financial expenditure by Anixa [S1].
• In May 2024, Anixa entered a Joint Development and Option Agreement with Cleveland Clinic to collaborate on additional cancer vaccines targeting lung, colon, and prostate cancers [S1].
• The company’s revenue to date has been derived from technology licensing and patent sales; it has not generated revenue from therapeutics or vaccine programs [S1].
• Anixa’s business model relies on strategic collaborations with commercial partners for manufacturing, marketing, and sales, as it currently lacks infrastructure for these activities [S1].
• As of April 30, 2026, Anixa had $1.477 million in cash and equivalents and $12.209 million in short-term investments, totaling $14.692 million in current assets against $1.501 million in current liabilities, yielding a current ratio of 9.79 and a cash ratio of 9.12 [S2].
• For the six months ended April 30, 2026, the company reported a net loss of $2.516 million and basic and diluted EPS of -$0.07 [S2].
• The company had $210,000 in revenue for the fiscal year ended October 31, 2024, primarily from licensing and patent-related activities [S1].
• Anixa had four full-time employees as of October 31, 2025, and collaborates with research teams at Moffitt and Cleveland Clinic [S1].
• The company faces risks typical of early-stage biotechnology firms, including clinical trial enrollment, regulatory approval uncertainties, competition from larger firms, supply chain risks for specialty raw materials, and the need for additional funding [S1, S2].
• There have been no material changes in risk factors between the 10-K for fiscal year ended October 31, 2025, and the 10-Q for the quarter ended April 30, 2026 [S1, S2].
• Recent news highlights include positive Phase 1 breast cancer vaccine data presented at the San Antonio Breast Cancer Symposium in December 2025, and continued buy recommendations from D. Boral Capital [N1, N2].
• News coverage notes Anixa’s stock performance relative to medical peers and highlights momentum interest in the company [N3, N4, N5].